It is only undervalued because, as previously commented on, the company is viewed as a company that focuses on developing innovative 'cannabinoid-based pharmaceuticals and dermatology products'. Also, it is still in the speccy area of the share market.
As we (the shareholders) all know by now, this is going to radically change in the near future. To be honest, I can't even predict how many bags we will make from this baby!
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)